Table 1.
Baseline characteristics of patients with gradable baseline DRSS.
| Laser control (n = 249) | IAI 2q4 (n = 250) | IAI 2q8 (n = 249) | IAI combined (n = 499) | Total (N = 748) | |
|---|---|---|---|---|---|
| Age, mean (SE), years | 62.6 (0.6) | 61.9 (0.6) | 63.4 (0.6) | 62.7 (0.4) | 62.7 (0.3) |
| Female, n (%) | 107 (43.0) | 103 (41.2) | 104 (41.8) | 207 (41.5) | 314 (42.0) |
| Duration of diabetes mellitus | |||||
| N | 247 | 248 | 248 | 496 | 743 |
| Mean (SE), years | 16.5 (0.6) | 15.6 (0.6) | 16.3 (0.7) | 15.9 (0.5) | 16.1 (0.4) |
| Haemoglobin A1c | |||||
| N | 248 | 246 | 249 | 495 | 743 |
| >8%, n (%) | 75 (30.1) | 95 (38.0) | 88 (35.3) | 183 (36.7) | 258 (34.5) |
| DRSS score, n (%) | |||||
| ≤43 | 108 (43.4) | 96 (38.4) | 97 (39.0) | 193 (38.7) | 301 (40.2) |
| 47 | 50 (20.1) | 44 (17.6) | 59 (23.7) | 103 (20.6) | 153 (20.5) |
| ≥53 | 91 (36.5) | 110 (44.0) | 93 (37.3) | 203 (40.7) | 294 (39.3) |
IAI intravitreal aflibercept injection, 2q4 2 mg q4 weeks, 2q8 2 mg q8 weeks after 5 initial monthly doses, SE standard error, DRSS Diabetic Retinopathy Severity Scale.